Postmenopausal Endometriosis: Clinical Insights and Imaging Considerations
review
OA: closed
public-domain-us
AI-generated summary
This paper reviews clinical insights and imaging considerations for postmenopausal endometriosis, a condition more common in women on hormone therapy, with a higher risk of malignant transformation, and discusses diagnostic roles of ultrasound and MRI.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Endometriosis is a chronic systemic condition characterized by the presence of ectopic endometrial-like tissue outside of the uterus. It occurs most often in reproductive-aged patients and less frequently in postmenopausal women. In postmenopausal patients, endometriosis is more common in those undergoing hormone replacement therapy or taking tamoxifen. The risk of malignant transformation of endometriosis is higher in this older population, especially in those undergoing estrogen-only hormone replacement therapy. Many theories on the postmenopausal pathogenesis of endometriosis have been proposed, ranging from reactivation of premenopausal disease to de novo manifestation. Compared with premenopausal disease, postmenopausal endometriosis is typically less active and extensive, with fewer hemorrhagic components. Patients may be symptomatic, with chronic pelvic pain, or may receive the diagnosis after imaging performed for other indications such as an incidental ovarian lesion. Treatment is typically surgical resection or estrogen-blocking medications. Although the diagnosis requires pathologic confirmation, radiologists play an important role in diagnosing both benign endometriosis and malignant transformation. Pelvic US following a dedicated protocol is an accessible screening tool, with high sensitivity for diagnosis of bowel-invasive disease. MRI has better anatomic resolution and allows simultaneous characterization of adnexal and extrapelvic lesions, thereby providing excellent assessment for malignant transformation.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
SciLite annotations
chemicals 3
tamoxifen
estrogen
estrogen
Source provenance
- europepmc
- last seen: 2026-09-12T06:55:35.949492+00:00
- pubmed
- last seen: 2026-09-12T06:52:04.780067+00:00
- scilite
- last seen: 2026-05-18T04:26:01.642840+00:00
- unpaywall
- last seen: 2026-09-12T07:21:10.926195+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine